Product Features
Introducing our launched product: Purocenta®, as well as veterinary drugs in development.
Purocenta®, with PTS as its Active Pharmaceutical Ingredient (API), is the first intra-tumoral injection to acquire marketing approval in China for the ablation of central airway tumors in non-small cell lung cancer (NSCLC) patients, as well as Gongwin's first product on the market.
Human Indication
In past clinical experience, PTS has been proven to have significant efficacy in a variety of solid tumor human indications, including head and neck/breast/lung/liver cancers.
Veterinary Indication
Gongwin Biopharm Co., Ltd. is also utilizing its core technology to develop tumor ablation formulas for companion animals in Taiwan. The company has completed the field trials for treating canine melanomas with PTS in 2024, and the registration process of p-TLS with CVM-USFDA & APVMA is ongoing.
Looking ahead, Gongwin is interested in exploring studies on the applications of p-TLS in the treatment of canine osteosarcomas and equine sarcoids.